Exposing Big Pharma’s Greed
Big Pharma has been playing a costly game, manipulating the patent system to keep drug prices sky-high—even on medications developed with taxpayer funding.
At Accountable.US, we’ve uncovered how drug manufacturers use tactics like pay-to-delay, evergreening, patent thickets, and product hopping to block generic competition and maintain their grip on the market. These strategies have allowed companies to rake in billions while Medicare and U.S. taxpayers foot the bill—leaving many patients, especially in lower-income and marginalized communities, struggling to afford the medications they need.
Explore our in-depth research, press releases, and latest news as we expose Big Pharma’s abuses and advocate for accountability in drug pricing. Learn how we’re fighting back against these unfair practices to ensure affordable access to life-saving medications for all Americans.
Press Releases
Press Releases
Merck, BMS Rake in Billions as Big Pharma Continues Price-Gouging Campaign
Today, pharmaceutical leaders Merck and Bristol Myers Squibb (BMS) each reported their Q3 2024 earnings, with results reaching $3.2 and $1.2 billion, respectively. Both companies manufacture drugs selected for the Biden-Harris administration’s historic Medicare price negotiation program and are actively pursuing legal action to halt the program’s i
Press Releases
Watchdog: Big Pharma Back in Court Defending “Right” to Price Gouge Seniors
Today, AstraZeneca, Bristol Myers Squibb and Janssen will deliver opening arguments before the Third Circuit Court of Appeals for their case against the Biden-Harris administration’s historic Medicare negotiation program. Since President Biden signed the Inflation Reduction Act into law, the pharmaceutical industry has filed at least 9 lawsuits
Press Releases
Novartis Doubles Profits While Suing to Block Biden-Harris Rx Drug Negotiation Program Lowering Seniors’ Costs
Today, Novartis—one of several pharmaceutical companies still suing the Biden-Harris administration to block Medicare from negotiating lower prescription drug prices—announced $3.2 billion in Q3 2024 earnings, a 111% increase from 2023, thanks to “sales growth driven by continued strong performance from Entresto.”
In The News
- Salon: Big Pharma “unleashed an army” of lawyers to avoid lowering Medicare drug costs: report
- Yahoo! Finance: Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions.
- Common Dreams: ‘New Era of Affordability’: Historic Medicare Negotiations Slash Drug Prices
- The Hill: Drugmakers in Medicare negotiations spent more on shareholder payments and marketing than R&D last year: Report
- Rolling Stone: How Big Pharma is Fueling a Radical MAGA Agenda
- The Guardian: US Pharma group opposing abortion pill restrictions also backs Republicans attacking drug
Additional Research
- Conservative Groups Push to Overturn Inflation Reduction Act After $1M in PhRMA Contributions
- Fifth Circuit Pharma Conflicts
- PhRMA Gave Nearly $30K in Illegal Dark Money to Fight Whitmer’s COVID Measures
- PhRMA Gave $16M to Block Drug Price Negotiations in 2022
- PhRMA Donates $300K to RAGA Despite Ongoing Legal Challenges
- PhRMA Gave $530K to Conservative Groups Tied to Leonard Leo and Project 2025 in 2022
- PhRMA’s Latest 2022 IRS Filing Shows Over $1.2 Million In Payments To Opponents of Medicare Drug Price Negotiations
- REPORT: Profits & Investor Handouts Soar Among Top 5 Pharma Companies Amid Industry Price Hikes
- Drug Company Insider Stock Dumping Surged as Taxpayer-Funded Vaccines Moved Toward Approval
Stay Informed
Get the latest news on how we’re holding big business, government officials, and special interests accountable, and what you can do to get involved.
By submitting your cell phone number, you are agreeing to receive period text messages from Accountable.US, including automated text messages. Message and data rates may apply. Text HELP for more information. Text STOP to stop receiving messages.